Researchers are exploring whether these ubiquitous fluorinated molecules might worsen infections or hamper vaccine effectiveness.
Image credit: Shutterstock/Dmitry Naumov.
Edited by Marcus E. Raichle, Washington University in St. Louis, St. Louis, MO, and approved February 3, 2017 (received for review July 21, 2016)
Significance
Postpartum blues is a healthy range of sadness that peaks on day 5 after giving birth in most women. Severe postpartum blues is a high-risk state for postpartum depression. A dietary supplement was designed to compensate for a temporary rise in a brain protein, monoamine oxidase A, which occurs on postpartum day 5. This study tested whether this dietary supplement reduces the sadness associated with the postpartum blues. Total levels of tryptophan and tyrosine in breast milk are not affected by this dietary supplement. Women received the dietary supplement over postpartum days 3–5 or received no supplement. This dietary supplement dramatically reduced the vulnerability to sadness on postpartum day 5, the peak of the postpartum blues, eliminating the prodrome of postpartum depression.
Abstract
Medical research is moving toward prevention strategies during prodromal states. Postpartum blues (PPB) is often a prodromal state for postpartum depression (PPD), with severe PPB strongly associated with an elevated risk for PPD. The most common complication of childbearing, PPD has a prevalence of 13%, but there are no widespread prevention strategies, and no nutraceutical interventions have been developed. To counter the effects of the 40% increase in monoamine oxidase A (MAO-A) levels that occurs during PPB, a dietary supplement kit consisting of monoamine precursor amino acids and dietary antioxidants was created. Key ingredients (tryptophan and tyrosine) were shown not to affect their total concentration in breast milk. The aim of this open-label study was to assess whether this dietary supplement reduces vulnerability to depressed mood at postpartum day 5, the typical peak of PPB. Forty-one healthy women completed all study procedures. One group (n = 21) received the dietary supplement, composed of 2 g of tryptophan, 10 g of tyrosine, and blueberry juice with blueberry extract. The control group (n = 20) did not receive any supplement. PPB severity was quantitated by the elevation in depressed mood on a visual analog scale following the sad mood induction procedure (MIP). Following the MIP, there was a robust induction of depressed mood in the control group, but no effect in the supplement group [43.85 ± 18.98 mm vs. 0.05 ± 9.57 mm shift; effect size: 2.9; F(1,39) = 88.33, P < 0.001]. This dietary supplement designed to counter functions of elevated MAO-A activity eliminates vulnerability to depressed mood during the peak of PPB.
Footnotes
- ↵1To whom correspondence should be addressed. Email: jeff.meyer{at}camhpet.ca.
Author contributions: Y.D., A.V.R., Z.V.S., D.E.S., M.S., and J.H.M. designed research; Y.D. and J.H.M. performed research; Y.D. and J.H.M. contributed new reagents/analytic tools; Y.D. and J.H.M. analyzed data; and Y.D. and J.H.M. wrote the paper.
Conflict of interest statement: Y.D. is developing natural health products to overcome a high MAO-A state in early postpartum. J.H.M. has received operating grant funding for other studies from Eli Lilly, GlaxoSmithKline, Bristol-Myers Squibb, Lundbeck, SK Life Science, and Johnson & Johnson/Janssen in the past 5 years. J.H.M. has served as a consultant for all of these companies except Johnson & Johnson, as well as for Sepracor, Trius Therapeutics, and Mylan Inc. None of these companies participated in the funding, design, or execution of this study or preparation of the manuscript. J.H.M. is developing natural health products to treat high-risk states for major depressive episode, and is listed as the inventor on a patent application for this dietary supplement. J.H.M. is applying for patents to implement measures using MAO to diagnose or treat mood disorders and to use peripheral measures as surrogate measures for brain inflammation. Z.V.S. receives royalties from Guilford Press for books related to mindfulness-based cognitive therapy and fees for training workshops. He also serves on the advisory board of MindfulNoggin, part of NogginLabs, a private company specializing in customized web-based learning. D.E.S. is a member of the scientific advisory board for the Cymbalta (duloxetine) Pregnancy Registry for Eli Lilly. She is a co-author of UpToDate chapters on antidepressant drugs during pregnancy and their effects on exposed infants. A.V.R. and M.S. do not have any conflicts of interest related to this work.
This article is a PNAS Direct Submission.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1611965114/-/DCSupplemental.
Dietary supplement for preventing postpartum blues
Sign up for Article Alerts
Jump to section
You May Also be Interested in
Recent experiments and simulations are starting to answer some fundamental questions about how life came to be.
Image credit: Shutterstock/Radoslaw Lecyk.
Archaeologists have long tried to define the transition between the two time periods.
Image credit: Ceri Shipton.
Adam Mastroianni and Daniel Gilbert explore why conversations almost never end when people want them to.
A study finds that giant pandas roll in horse manure to increase their cold tolerance.
Image credit: Fuwen Wei.